Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Walmart Stores Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.93 (market cap $29.60B), while Walmart Stores Inc trades at $115.33 (market cap $901.33B). The key difference: Walmart Stores Inc is far larger — about 30.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Walmart Stores Inc pays a 0.87% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WMT | |
|---|---|---|
Market Cap | $29.60B | $901.33B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $134.20 |
52-Week Low | $205.48 | $96.05 |
Enterprise Value | $27.56B | $964.78B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Walmart (WMT) trades at $112.66, up 0.72% with strong fundamental performance including three consecutive quarterly EPS beats and robust revenue growth to $681B in 2025. The stock shows neutral technical signals with RSI at 62.52, while analyst consensus remains strongly bullish with a $142 price target. Recent developments include AI tool innovations and expanded delivery services positioning the company for continued market leadership.
Walmart presents a compelling investment case with solid fundamentals and analyst support, though valuation multiples appear elevated. Key opportunities include sustained revenue growth and operational efficiency gains, while risks involve competitive pressures from Amazon and potential margin compression. The stock offers 26% upside to consensus targets but requires monitoring of execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
